Affiliation:
1. Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Science, 1432–1 Horinouchi, Hachioji, Tokyo 192–03
2. 3rd Department of Internal Medicine, Tokyo Medical College, Nishishinjuku, Shinjuku-ku, Tokyo 160–0023, Japan
Abstract
Abstract
The anti-hypertensive properties of dehydroepiandrosterone sulphate (DHEAS) have been investigated by studying its effects on blood pressure, on serum concentrations of corticosterone and dehydrocorticosterone, and on 11 β-hydroxysteroid dehydrogenase (11 β-HSD) activity in spontaneously hypertensive rats (SHR).
SHR were given intraperitoneal injections of DHEAS (10 mg day−1 for 70 days) from six to 16 weeks of age. The blood pressure–time curve was significantly (P<0.05) suppressed immediately after administration of DHEAS. There was no difference between the heart rates of control and DHEAS groups. Serum concentrations of corticosterone and dehydrocorticosterone in the DHEAS group were significantly (P < 0.05) lower than those of the control group. The dehydrocorticosterone/corticosterone concentration ratio was, however, significantly (P < 0.05) higher in the DHEAS group, suggesting that treatment with DHEAS enhanced the overall interconversion of corticosterone to dehydrocorticosterone. The activity of 11 β-HSD in specific organs of the DHEAS group was affected, characteristic changes being increases in the kidney (14–58%), decreases in the liver (11–27%) and no change in the testis. Direct addition of DHEAS to 11 β-HSD preparations from the kidneys of control SHR had the same effect as that observed in the in-vivo experiments.
The fall in serum corticosterone in the DHEAS group is considered to be related, at least partly, to increased activity of kidney 11 β-HSD. The inverse correlation of kidney 11 β-HSD activity with serum corticosterone and blood pressure (—r = 0.628, P < 0.01, and —r = 0.478, P < 0.05, respectively) suggest that DHEAS delayed the development of hypertension in SHR by selective promotion of kidney 11 β-HSD activity which in turn resulted in lower serum concentrations of corticosterone and its minimal aldosterone-like activity.
Funder
Ministry of Education in Japan
Publisher
Oxford University Press (OUP)
Subject
Pharmaceutical Science,Pharmacology
Reference24 articles.
1. Dehydroepiandrosterone (DHEA): a fountain of youth?;Baulieu;J. Clin. Endocrinol. Metab.,1996
2. The calcium-channel blocker amlodipine raises serum dehydroepiandrosterone sulphate and androstenedione but lowers serum cortisol, in insulin-resistant obese and hypertensive men;Beer;J. Clin. Endocrinol. Metab.,1993
3. Disparate effects of insulin reduction with diltiazem on serum dehydroepiandrosterone sulphate levels in obese hypertensive men and women;Beer;J. Clin. Endocrinol. Metab.,1994
4. A prospective study of dehydroepiandrosterone sulphate, mortality, and cardiovascular disease;Connor;N. Eng. J. Med.,1986
5. Alterations in cortisol metabolism in insulin-dependent diabetes mellitus: relationship with metabolic control and estimated blood volume and effect of angiotensin-converting enzyme inhibition;Dullaart;J. Clin. Endocrinol. Metab.,1995
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献